Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
£0.00
+£0.00 (+0.00%)
EOD Jul 3, 2026
The business is unprofitable at the operating level (-898.99% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 10.4% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -54.99% to -73.22%, capital efficiency is deteriorating. Negative free cash flow of -£3M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£396K
▼ -10.4% YoY
Net Income (TTM)
-£3M
▲ +22.4% YoY
Op. Margin
-898.99%
▲ +248.1pp YoY
ROIC
-73.22%
▼ -18.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£3M
▲ +27.4% YoY
Op. Cash Flow (TTM)
-£3M
▲ +27.4% YoY
Net Debt
-£2M
Net Cash Position
Cash & Equiv.
£2M
3Y CAGR: +26.9%
Continue Research
Evgen Pharma (EVG.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Evgen Pharma scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Evgen Pharma scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -899.0% operating margin and a -73.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh EVG.XLON's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.